Sign In
Buy ACET
$7.83
-0.280 (-3.45%)
At Close: Jun 03, 2026
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones
04:10pm, Wednesday, 08'th Jan 2025
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
04:48pm, Tuesday, 31'st Dec 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
07:00am, Thursday, 19'th Dec 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer
07:00am, Wednesday, 18'th Dec 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
04:44pm, Friday, 29'th Nov 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
04:00pm, Monday, 18'th Nov 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmu
Adicet Bio to Participate in Upcoming Investor Conferences
07:00am, Friday, 01'st Nov 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05:31pm, Thursday, 31'st Oct 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05:08pm, Monday, 30'th Sep 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases
07:00am, Monday, 30'th Sep 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
07:00am, Thursday, 19'th Sep 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
UL Solutions Warns of Potentially Hazardous Communications Cable
07:13pm, Friday, 30'th Aug 2024
NORTHBROOK, Ill.--(BUSINESS WIRE)--The following is a notification from UL Solutions that the communications cable that bears the serial numbers identified below may pose a potential fire hazard. The
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05:44pm, Friday, 30'th Aug 2024
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
